Wed.Jul 31, 2024

article thumbnail

Bayer lops off 70 more employees at New Jersey headquarters

Fierce Pharma

Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more workers at the site. | Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification.

299
299
article thumbnail

Biotech Startup AIRNA Adds $60M to Advance RNA-Editing Therapy for Rare Protein Deficiency

MedCity News

AIRNA’s therapy for alpha1 antitrypsin deficiency, or AATD, edits RNA to address the underlying cause of this rare inherited disease. Wave Life Sciences and Korro Bio are both further along in the development of RNA-editing therapies for AATD, but AIRNA claims its therapy could be best in class. The post Biotech Startup AIRNA Adds $60M to Advance RNA-Editing Therapy for Rare Protein Deficiency appeared first on MedCity News.

Biopharma 114
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J touts new 'foundational' frontline multiple myeloma treatment as Darzalex Faspro nabs quadruplet FDA nod

Fierce Pharma

On the heels of game-changing trial results presented at la | On the heels of game-changing trial results presented at last year's ASH meeting, J&J is introducing what it calls a "foundational frontline therapy" in multiple myeloma and at the same time expanding its already impressive presence in the field.

FDA 252
article thumbnail

Vertex eyes FDA decision on non-opioid pain drug in January

pharmaphorum

Vertex has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year

FDA 110
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

GSK cuts vaccine sales outlook after RSV surprise, but CEO puts on bold front on peak potential

Fierce Pharma

The whole respiratory syncytial virus (RSV) vaccine field took a beating when the Centers for Disease Control and Prevention’s (CDC's) immunization committee doled out a limited recommendation last | The whole RSV vaccine field took a beating when the CDC’s immunization committee doled out a limited recommendation last month. And it’s showing in GSK’s forecast for 2024, just as the company’s Shingrix disappointed.

Sales 231
article thumbnail

Magazine: Left in limbo: when pharma halts rare disease research

Pharmaceutical Technology

Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.

Pharma 98

More Trending

article thumbnail

How Are Health Systems and Health Tech Addressing Cybersecurity? A Timely Panel Discussion at INVEST Digital Health

MedCity News

At the INVEST Digital Health conference on September 18 at Pegasus Park in Dallas, cybersecurity will be part of the conversation. A panel will highlight how hospitals are dealing with the security threat such as HHS policies, staff training, and more. The post How Are Health Systems and Health Tech Addressing Cybersecurity? A Timely Panel Discussion at INVEST Digital Health appeared first on MedCity News.

Training 104
article thumbnail

Takeda's Entyvio holds onto IBD market share despite threat from AbbVie's Skyrizi

Fierce Pharma

Even with new entrants edging into the crowded irritable bowel disease (IBD) market and potentially threatening Entyvio’s spot as the market leader, Takeda figures its product still has room to gro | With a new subcutaneous formulation for Entyvio, the Japanese drugmaker isn't worried about new entrants affecting its leading spot in the first-line IBD market over the long run.

Marketing 202
article thumbnail

988 Turns Two: What’s Next for the Crisis Response Lifeline?

MedCity News

It’s time for technology to deliver the tools that will help healthcare professionals respond to a mental health or substance misuse crisis with the same urgency we extend to patients experiencing a physical health emergency. The post 988 Turns Two: What’s Next for the Crisis Response Lifeline? appeared first on MedCity News.

article thumbnail

Teva rides growth momentum through Q2, boosts '24 sales outlook

Fierce Pharma

Teva and its long-term investors have been through much disappointment over the last decade, but 2024 is bringing optim | Teva has boosted its revenue and profit outlook for the year after reporting a strong quarter for its generics business. The company's key growth driver Austedo contributed to the performance, as well.

Sales 202
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Healthcare Moves: A Monthly Summary of Hires and Layoffs

MedCity News

Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.

article thumbnail

Eisai, Biogen show Leqembi provides added benefits over time as Alzheimer's showdown with Lilly heats up

Fierce Pharma

Three-year data from a study of early Alzheimer’s disease (AD) patients on Eisai and Biogen’s Leqembi showed that longer-term use provi | Three-year data from a study of early Alzheimer’s disease patients on Eisai and Biogen’s Leqembi showed that longer-term use provides continued benefits without additional safety concerns.

Safety 262
article thumbnail

The Crucial Role of Non-Emergency Medical Transportation Providers in Driving Health Equity

MedCity News

When we consider the value of NEMT services, it’s critical to start with how these services impact the individual. Transport providers are on the frontlines of helping to ensure equal access to care and prevent long-term health issues that may arise from missed appointments. The post The Crucial Role of Non-Emergency Medical Transportation Providers in Driving Health Equity appeared first on MedCity News.

article thumbnail

Quantifying Impact of the Customer Experience on PSP Outcomes

Fierce Pharma

MELISSA CONNOLLY, Associate Principal, Strategy Consulting, IQVIAJESSICA MESERVEY, Senior Principal, Patient Engagement, IQVIA | Pharma often measures customer experiences rigorously, but PSPs lack this focus. IQVIA, with a top pharma company, created a framework to improve PSP evaluation.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

3 Big Pharma cancer drugs facing inflation penalties

PharmaVoice

The U.S. government will demand payment from Big Pharma to make up for dozens of drugs with prices that rose faster than the rate of inflation.

Pharma 98
article thumbnail

GSK raises forecasts for 2024, but shares slide

pharmaphorum

GSK raises 2024 forecasts on a strong Q2 led by HIV and cancer drugs, but its shares weakened on litigation concerns and weaker vaccine expectations

100
100
article thumbnail

FDA approves J&J’s multiple myeloma therapy

Pharmaceutical Technology

The US FDA has granted approval for Johnson & Johnson’s (J&J) DARZALEX FASPRO for treating newly diagnosed multiple myeloma (NDMM).

FDA 97
article thumbnail

Patients resist Novo Nordisk plan to stop making Levemir

pharmaphorum

Patient advocacy group APIC has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir

Patients 101
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

MSD reports net income of $5.4bn in Q2 2024

Pharmaceutical Technology

MSD has reported a net income on a GAAP basis of $5.4bn for Q2 2024 compared to the net loss of $5.9bn in the same quarter of 2023.

98
article thumbnail

Zing Health, Story Health Partner To Bring Cardiology Support to At-Risk Members

MedCity News

Story Health is now providing cardiovascular support to Zing Health’s members. They’ll get access to a care team that includes cardiologists, cardiac nurse practitioners, registered nurses and health coaches. The post Zing Health, Story Health Partner To Bring Cardiology Support to At-Risk Members appeared first on MedCity News.

86
article thumbnail

Pfizer’s Q2 2024 net income attributable to shareholders down 98%

Pharmaceutical Technology

Pfizer has posted a 98% decrease in net income attributable to shareholders of $41m for Q2 2024, compared to $2.3bn in Q2 2023.

98
article thumbnail

After EU setback, Eisai/Biogen build case for Leqembi

pharmaphorum

Eisai, Biogen report data showing benefit of Alzheimer's disease therapy Leqembi builds with time, with no increase in safety risk

Safety 97
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Sales Retention: Will You Be Able to Keep Your Superstars In The Future?

Integrity Solutions

Money and incentives matter, but they are only part of the sales retention story. The pace of transformation and continual shifting conditions in the business environment over the past few years have made us all feel like we’re on a roller coaster ride — and you can be sure there will be many more ups and downs and twists and turns ahead.

Sales 66
article thumbnail

FibroGen wields axe as pancreatic cancer drug is canned

pharmaphorum

FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.The San Francisco biotech confirmed that neither the PanCAN Precision Promise study in metastatic pancreatic cancer nor the LAPIS trial in patients with locally advanced, unresectable pancreatic cancer had shown an improvement in overall survival (OS) with the drug.

Leads 71
article thumbnail

EPSRC launches two new hubs to transform early disease diagnosis in the UK

PharmaTimes

Quantum-based technologies will explore infectious diseases, cancer and dementia

article thumbnail

Pharma Pulse 7/31/24: In the Specialty Drug Spend — Biologics Rule, Big Pharma Rallies and Moves Past Obesity & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 102
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Apollo and Oxford University enter drug discovery and development collaboration

PharmaTimes

The latest collaboration marks Apollo’s sixth agreement with a research institution

89
article thumbnail

FDA Approves Johnson & Johnson’s Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

PharmExec

Results from the PERSEUS study led to the FDA approval of Darzalex Faspro in patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.

FDA 52
article thumbnail

Scalable Solutions for Novel Oral Solid Dose Development and Manufacturing

PharmaTech

Developing successful oral solid dosage forms necessitates partnering with a CDMO equipped with distinctive technologies and expertise to enable support across solid-state characterization, formulation development and scale-up manufacturing processes.

article thumbnail

Succeeding In The Laser Aesthetic Sales Industry With Derek Sanz

Evolve Your Success

Unlock the secrets of the booming laser aesthetics industry with Derek Sanz, a seasoned expert with two decades in medical devices and med-tech. Discover why more dermatologists, plastic surgeons, and med spas are flocking to this elective, cash-pay market. Derek shares invaluable insights on the diverse array of treatments, the appeal of high-end devices, and why the industry is shifting away from requiring a college degree.

Sales 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.